EXOZ (invizyne.com) יחס שווי שוק לשווי בספרים
eXoZymes Inc (EXOZ) monetizes its innovative SimpleCell system, generating profit through royalties and direct agreements with industry behemoths. The business model is based on granting cell-free compound synthesis rights to external partners. The startup is currently actively forming scientific and technical alliances to verify its developments, with the indicator standing at 9.82. This chart of the company's current market value is available on the GURU.Markets platform.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_EXOZ_-_eXoZymes-Inc_-_Market-Capitalization-to-Net-Assets "EXOZ יחס שווי שוק לערך בספרים Invizyne (13.02.2025 - 28.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Invizyne Technologies (EXOZ)
This ratio determines the premium or discount of a business's market value relative to its net assets, revealing the extent to which fundamental indicators are overvalued. Analyzing the ratio of current market capitalization to its balance sheet allows for an assessment of how investors are actually capitalizing the strategic alliances of eXoZymes Inc (EXOZ) regarding cell-free enzyme synthesis and production cost reductions compared to the actual value of the company's resources.